Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Cediranib and lenalidomide in iodine 131-refractory differentiated thyroid cancer

Ari Rosenberg, MD, Yale School of Medicine, New Haven, CT, discusses the results of a randomized Phase II clinical trial evaluating cediranib, an anti-VEGF tyrosine kinase inhibitor (TKI), with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Cediranib alone had an objective response rate (ORR) consistent with many other VEGF receptor-targeted therapies in thyroid cancer. However, lenalidomide did not appear to improve response or progression free survival (PFS), compared with cediranib alone in differentiated thyroid cancer. The main findings reinforces the clinical activity of VEGF receptor-targeted TKIs, and that lenalidomide should not be combined with VEGF receptor-targeted therapy. Improved frontline combinations with VEGF receptor-targeted tyrosine kinase inhibitor are required to improve response and PFS. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.